Search Results - "Oxlund, C."

Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension by Oxlund, C S, Cangemi, C, Henriksen, J E, Jacobsen, I A, Gram, J, Schousboe, K, Tarnow, L, Argraves, W S, Rasmussen, L M

“…Diabetic patients with hypertension are at particularly high risk of vascular damage and consequently cardiovascular and renal disease. Fibulin-1, an…”
Get full text

419Body mass index and intensive blood pressure management in high-risk adults: insights from the systolic blood pressure intervention trial SPRINT by Pareek, M, Vaduganathan, M, Biering-Sorensen, T, Oxlund, C S, Rasmussen, B S, Olsen, M H, Bhatt, D L

Get full text

PP.28.10: ALDOSTERONE-MINERALOCORTICOID RECEPTOR PROMOTES URINE PROSTASIN THROUGH GLOMERULAR BARRIER INJURY AND NOT TISSUE ABUNDANCE by Oxlund, C., Kurt, B., Schwarzensteiner, I., Hansen, M., Steahr, M., Svenningsen, P., Toft, A., Henrichs, G., Bistrup, C., Jacobsen, I., Jensen, B.

Get full text

The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension by Thangaraj, Sai Sindhu, Oxlund, Christina Stolzenburg, Fonseca, Micaella Pereira Da, Svenningsen, Per, Stubbe, Jane, Palarasah, Yaseelan, Ketelhuth, Daniel F.J., Jacobsen, Ib. Abildgaard, Jensen, Boye L.

“…The mineralocorticoid receptor antagonist spironolactone lowers blood pressure in patients with resistant hypertension despite antihypertensive treatment with…”
Get full text